Seroquel XR FDA Approval History
Seroquel XR (quetiapine) is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia, bipolar disorder and as an adjunctive treatment to antidepressants in adults with Major Depressive Disorder.
Development Timeline for Seroquel XR
|Dec 4, 2009||Approval FDA Approves Seroquel XR For Add-On Treatment of Major Depressive Disorder|
|Oct 10, 2008||Approval FDA Approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US|
|Nov 16, 2007||Approval Seroquel XR Receives Approval From FDA for Maintenance Treatment ofSchizophrenia|
|May 18, 2007||Approval FDA Approves Astrazeneca's Once-Daily Seroquel XR Extended-ReleaseTablets for the Treatment of Schizophrenia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.